Levosimendan Kalceks (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which strengthens heart muscle contraction without raising intracellular calcium levels. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing the workload on the heart.

The dosing regimen for levosimendan is individualized and determined by the prescribing physician based on the patient’s clinical status, weight, and response. The medication is administered intravenously under continuous monitoring in a hospital setting.

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be ruled out, it is generally avoided in pregnant or breastfeeding women unless the expected benefit justifies the potential hazard to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without increasing intracellular calcium, reducing the risk of calcium‑mediated toxicity. Its combined inotropic and vasodilatory actions often result in better hemodynamic stability and may lower the incidence of arrhythmias compared with agents such as dobutamine or dopamine.

Levosimendan Kalceks should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Levosimendan is given as an intravenous infusion, typically started with a loading dose followed by a continuous maintenance infusion. Administration occurs in a monitored clinical environment, allowing real‑time assessment of blood pressure, heart rate, and cardiac output.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for sudden drops in blood pressure, abnormal heart rhythms, and chest pain or ECG changes indicating reduced coronary perfusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving concurrent strong vasodilators that could precipitate dangerous blood pressure falls. Caution is also advised in individuals with significant hepatic or renal impairment.